To learn about enrollment criteria for our current clinical trials and for whom to contact for further information, please click on the links provided. If you think that you meet the criteria shown, please contact the appropriate study coordinator for further information.
- Phase 2/3 study of PCC + bevacizumab +/- CA4P in platinum-resistant ovarian cancer (FOCUS Study; NCT02641639), please visit focusclinicalstudy.com
- Phase 1b/2study of pazopanib +/- CA4P in advanced recurrent ovarian cancer (PAZOFOS Study; NCT02055690), please visit clinicaltrials.gov
- Phase 1b/2 study of OXi4503 (NCT02576301) in patients with relapsed and refractory myelogenous leukemia (AML) or myelodysplastic syndrome (MDS), please visit clinicaltrials.gov
Expanded Access Policy: At this time, Mateon Therapeutics does not offer an expanded access program for investigational medicines being evaluated in our clinical trials.